Literature DB >> 26354989

Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.

Lisa Wang1, Jan O Aasly1, Grazia Annesi1, Soraya Bardien1, Maria Bozi1, Alexis Brice1, Jonathan Carr1, Sun J Chung1, Carl Clarke1, David Crosiers1, Angela Deutschländer1, Gertrud Eckstein1, Matthew J Farrer1, Stefano Goldwurm1, Gaetan Garraux1, Georgios M Hadjigeorgiou1, Andrew A Hicks1, Nobutaka Hattori1, Christine Klein1, Beom Jeon1, Yun J Kim1, Suzanne Lesage1, Juei-Jueng Lin1, Timothy Lynch1, Peter Lichtner1, Anthony E Lang1, Vincent Mok1, Barbara Jasinska-Myga1, George D Mellick1, Karen E Morrison1, Grzegorz Opala1, Lasse Pihlstrøm1, Peter P Pramstaller1, Sung S Park1, Aldo Quattrone1, Ekaterina Rogaeva1, Owen A Ross1, Leonidas Stefanis1, Joanne D Stockton1, Peter A Silburn1, Jessie Theuns1, Eng K Tan1, Hiroyuki Tomiyama1, Mathias Toft1, Christine Van Broeckhoven1, Ryan J Uitti1, Karin Wirdefeldt1, Zbigniew Wszolek1, Georgia Xiromerisiou1, Kuo-Chu Yueh1, Yi Zhao1, Thomas Gasser1, Demetrius M Maraganore1, Rejko Krüger1, Manu Sharma2.   

Abstract

OBJECTIVES: We aim to clarify the pathogenic role of intermediate size repeat expansions of SCA2, SCA3, SCA6, and SCA17 as risk factors for idiopathic Parkinson disease (PD).
METHODS: We invited researchers from the Genetic Epidemiology of Parkinson's Disease Consortium to participate in the study. There were 12,346 cases and 8,164 controls genotyped, for a total of 4 repeats within the SCA2, SCA3, SCA6, and SCA17 genes. Fixed- and random-effects models were used to estimate the summary risk estimates for the genes. We investigated between-study heterogeneity and heterogeneity between different ethnic populations.
RESULTS: We did not observe any definite pathogenic repeat expansions for SCA2, SCA3, SCA6, and SCA17 genes in patients with idiopathic PD from Caucasian and Asian populations. Furthermore, overall analysis did not reveal any significant association between intermediate repeats and PD. The effect estimates (odds ratio) ranged from 0.93 to 1.01 in the overall cohort for the SCA2, SCA3, SCA6, and SCA17 loci.
CONCLUSIONS: Our study did not support a major role for definite pathogenic repeat expansions in SCA2, SCA3, SCA6, and SCA17 genes for idiopathic PD. Thus, results of this large study do not support diagnostic screening of SCA2, SCA3, SCA6, and SCA17 gene repeats in the common idiopathic form of PD. Likewise, this largest multicentered study performed to date excludes the role of intermediate repeats of these genes as a risk factor for PD.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354989      PMCID: PMC4617164          DOI: 10.1212/WNL.0000000000002016

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci.

Authors:  P C Sham; D Curtis
Journal:  Ann Hum Genet       Date:  1995-01       Impact factor: 1.670

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings.

Authors:  S Furtado; M Farrer; Y Tsuboi; M L Klimek; R de la Fuente-Fernández; J Hussey; P Lockhart; D B Calne; O Suchowersky; A J Stoessl; Z K Wszolek
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

7.  Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family.

Authors:  K Gwinn-Hardy; A Singleton; P O'Suilleabhain; M Boss; D Nicholl; A Adam; J Hussey; P Critchley; J Hardy; M Farrer
Journal:  Arch Neurol       Date:  2001-02

8.  The parkinsonian phenotype of spinocerebellar ataxia type 2.

Authors:  Chin-Song Lu; Yah-Huei Wu Chou; Pei-Chi Kuo; Hsiu-Chen Chang; Yi-Hsin Weng
Journal:  Arch Neurol       Date:  2004-01

9.  Accurate determination of ataxin-2 polyglutamine expansion in patients with intermediate-range repeats.

Authors:  Jennifer Hussey; Paul J Lockhart; William Seltzer; Zbigniew K Wszolek; Haydeh Payami; Melissa Hanson; Katrina Gwinn-Hardy; Matt Farrer
Journal:  Genet Test       Date:  2002

Review 10.  Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis.

Authors:  Ludger Schöls; Peter Bauer; Thorsten Schmidt; Thorsten Schulte; Olaf Riess
Journal:  Lancet Neurol       Date:  2004-05       Impact factor: 44.182

View more
  7 in total

1.  The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Efthimios Dardiotis; Athina-Maria Aloizou; Vasileios Siokas; George P Patrinos; Georgia Deretzi; Panayiotis Mitsias; Michael Aschner; Aristidis Tsatsakis
Journal:  J Mol Neurosci       Date:  2018-11-10       Impact factor: 3.444

2.  Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6.

Authors:  Tao Xie; Daniel Appelbaum; Jacqueline Bernard; Mahesh Padmanaban; Yonglin Pu; Christopher Gomez
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

3.  ATXN2 a culprit with multiple facets.

Authors:  Aurore Nkiliza; Marie-Christine Chartier-Harlin
Journal:  Oncotarget       Date:  2017-05-23

4.  Co-occurrence of ATXN3 and ATXN2 repeat expansions in Chinese ataxia patients with slow saccades.

Authors:  Chao Wu; Qiong Cai; Huajing You; Xiangxue Zhou; Dingbang Chen; Guiling Mo; Xunhua Li
Journal:  Mol Genet Genomic Med       Date:  2019-03-28       Impact factor: 2.183

5.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

Review 6.  What is the Pathogenic CAG Expansion Length in Huntington's Disease?

Authors:  Jasmine Donaldson; Sophie Powell; Nadia Rickards; Peter Holmans; Lesley Jones
Journal:  J Huntingtons Dis       Date:  2021

Review 7.  The Multiple Faces of Spinocerebellar Ataxia type 2.

Authors:  Antonella Antenora; Carlo Rinaldi; Alessandro Roca; Chiara Pane; Maria Lieto; Francesco Saccà; Silvio Peluso; Giuseppe De Michele; Alessandro Filla
Journal:  Ann Clin Transl Neurol       Date:  2017-08-10       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.